FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael O'Donnell

Research Profile

Disorders

Chemicals & Drugs

Procedures

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Joseph A Gillespie; Michael A O'Donnell
New imaging techniques for non-muscle invasive bladder cancer: ready for primetime.
Andrew J Lightfoot; Kenneth G Nepple; Henry M Rosevear; Michael A O'Donnell
Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer.
Nathan A Bockholt; Michael D Eisenbraun; James D Fraser; Jonathan R Henning; Matthew J Knudson; José L Maymí; Michael A O'Donnell; George J Smith; Peter Weady; Yi Luo
Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael O'Donnell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Joseph A Gillespie; Michael A O'Donnell
New imaging techniques for non-muscle invasive bladder cancer: ready for primetime.
The Urologic clinics of North America 2013;40(2):271-9.
2012: Andrew J Lightfoot; Kenneth G Nepple; Henry M Rosevear; Michael A O'Donnell
Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer.
International journal of urology : official journal of the Japanese Urological Association 2012;19(11):988-93.
2012: Nathan A Bockholt; Michael D Eisenbraun; James D Fraser; Jonathan R Henning; Matthew J Knudson; José L Maymí; Michael A O'Donnell; George J Smith; Peter Weady; Yi Luo
Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
The Journal of urology 2012;187(6):2228-35.
2012: Eric J Askeland; Mark R Newton; Michael A O'Donnell; Yi Luo
Bladder Cancer Immunotherapy: BCG and Beyond.
Advances in urology 2012;2012():181987.
2011: Henry M Rosevear; Kevin K Birusingh; Andrew J Lightfoot; José L Maymí; Kenneth G Nepple; Michael A O'Donnell
Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
The Journal of urology 2011;186(3):817-23.
2011: Yi Luo; Jonathan Henning; Michael A O'Donnell
Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.
Clinical & developmental immunology 2011;2011():728930.
2011: Henry M Rosevear; Andrew J Lightfoot; Kenneth G Nepple; Michael A O'Donnell
Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.
The Journal of urology 2011;185(1):67-71.
2011: Thomas Griffith; Tamara Kucaba; Michael A O'Donnell; Jennifer Burns; Christopher Benetatos; Mark A McKinlay; Stephen Condon; Srinivas Chunduru
Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.
Apoptosis : an international journal on programmed cell death 2011;16(1):13-26.
2010: Kenneth G Nepple; Andrew J Lightfoot; Henry M Rosevear; Michael A O'Donnell; Donald L Lamm
Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
The Journal of urology 2010;184(5):1915-9.
2010: Henry M Rosevear; Andrew J Lightfoot; Kenneth G Nepple; Michael A O'Donnell
Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.
The Journal of urology 2010;184(5):1920-4.
2009: Kenneth G Nepple; Michael A O'Donnell
The optimal management of T1 high-grade bladder cancer.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2009;3(6 Suppl 4):S188-92.
2009: Henry M Rosevear; Andrew J Lightfoot; Michael A O'Donnell; Thomas Griffith
The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Cancer metastasis reviews 2009;28(3-4):345-53.
2009: Michael A O'Donnell
When medical evidence alone is simply not enough.
Cancer 2009;115(12):2602-4.
2009: Kenneth G Nepple; Howard A Aubert; Matthew R Braasch; Michael A O'Donnell
Combination of BCG and interferon intravesical immunotherapy: an update.
World journal of urology 2009;27(3):343-6.
2009: Michael A O'Donnell
Optimizing BCG therapy.
Urologic oncology 2009;27(3):325-8.
2009: Necole M Streeper; Christopher M Simons; Badrinath R Konety; DeSirae M Muirhead; Richard D Williams; Michael A O'Donnell; Fadi N Joudi
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
BJU international 2009;103(4):475-9.
2009: Kenneth G Nepple; Fadi N Joudi; Michael A O'Donnell
Review of topical treatment of upper tract urothelial carcinoma.
Advances in urology 2009;():472831.
2008: Matthew R Braasch; Andreas Böhle; Michael A O'Donnell
Risk-adapted use of intravesical immunotherapy.
BJU international 2008;102(9 Pt B):1254-64.
2008: Michael A O'Donnell
Does the probiotic L. casei help prevent recurrence after transurethral resection for superficial bladder cancer?
Nature clinical practice. Urology 2008;5(10):526-7.
2008: Mark P Simons; Michael A O'Donnell; Thomas Griffith
Role of neutrophils in BCG immunotherapy for bladder cancer.
Urologic oncology 2008;26(4):341-5.
2008: Brian L Gallagher; Fadi N Joudi; José L Maymí; Michael A O'Donnell
Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
Urology 2008;71(2):297-301.
2007: Anthony A Ryan; Teresa M Wozniak; Elena Shklovskaya; Michael A O'Donnell; Barbara Fazekas De St Groth; Warwick J Britton; James A Triccas
Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(12):8418-24.
2007: Xiaohong Chen; Michael A O'Donnell; Yi Luo
Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells.
Clinical and experimental immunology 2007;149(1):178-85.
2007: Andrew J Lightfoot; Mary Eno; Karl J Kreder; Michael A O'Donnell; Satish S C Rao; Richard D Williams
Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythromycin.
Urology 2007;69(4):611-5.
2007: Michael A O'Donnell
Advances in the management of superficial bladder cancer.
Seminars in oncology 2007;34(2):85-97.
2007: Yi Luo; Xiaohong Chen; Michael A O'Donnell
Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.
Clinical and experimental immunology 2007;147(2):370-8.
2006: Michael A O'Donnell; Andreas Boehle
Treatment options for BCG failures.
World journal of urology 2006;24(5):481-7.
2006: Michael A O'Donnell
Can a point-of-care urine protein assay monitor bladder cancer recurrence?
Nature clinical practice. Oncology 2006;3(9):482-3.
2006: Fadi N Joudi; Brian J Smith; Michael A O'Donnell
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
Urologic oncology 2006;24(4):344-8.
2006: Shital C Shah; Andrew Kusiak; Michael A O'Donnell
Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment.
Computers in biology and medicine 2006;36(6):634-55.
2006: Fadi N Joudi; Brian J Smith; Michael A O'Donnell; Badrinath R Konety
The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.
The Journal of urology 2006;175(5):1634-9; discussion 1639-40.
2006: Fadi N Joudi; Curtis N Crane; Michael A O'Donnell
Minimally invasive management of upper tract urothelial carcinoma.
Current urology reports 2006;7(1):23-30.
2006: Daniel K Lee; Veerasathpurush Allareddy; Michael A O'Donnell; Richard D Williams; Badrinath R Konety
Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?
BJU international 2006;97(1):48-50.
2005: Michael A O'Donnell
Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer.
The Urologic clinics of North America 2005;32(2):121-31.
2005: Aaron T Ludwig; Lavanya Inampudi; Michael A O'Donnell; Karl J Kreder; Richard D Williams; Badrinath R Konety
Two-surgeon versus single-surgeon radical cystectomy and urinary diversion: impact on patient outcomes and costs.
Urology 2005;65(3):488-92.
2005: Hiroshi Yamada; Yi Luo; Tetsuro Matsumoto; Michael A O'Donnell
A novel expression of macrophage derived chemokine in human bladder cancer.
The Journal of urology 2005;173(3):990-5.
2004: Yi Luo; Xiaohong Chen; Michael A O'Donnell
Use of prostate specific antigen to measure bladder tumor growth in a mouse orthotopic model.
The Journal of urology 2004;172(6 Pt 1):2414-20.
2004: Badrinath R Konety; Vibhu Dhawan; Veerasathpurush Allareddy; Michael A O'Donnell
Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper?
The Journal of urology 2004;172(3):1056-61.
2004: Michael A O'Donnell; Kathleen Lilli; Christina Leopold
Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer.
The Journal of urology 2004;172(3):888-93.
2004: Fadi N Joudi; Michael A O'Donnell
Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures.
Current opinion in urology 2004;14(5):271-5.
2004: Yi Luo; H Yamada; Xiaohong Chen; Anthony A Ryan; David Evanoff; James A Triccas; Michael A O'Donnell
Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Clinical and experimental immunology 2004;137(1):24-34.
2004: Aaron T Ludwig; Jill M Moore; Yi Luo; Xiaohong Chen; Nicole A Saltsgaver; Michael A O'Donnell; Thomas Griffith
Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.
Cancer research 2004;64(10):3386-90.
2004: Michael A O'Donnell; Yi Luo; Sharon E Hunter; Xiaohong Chen; Lori L Hayes; Steven K Clinton
The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
The Journal of urology 2004;171(3):1336-42.
2004: Michael A O'Donnell; Yi Luo; Sharon E Hunter; Xiaohong Chen; Lori L Hayes; Steven K Clinton
Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
The Journal of urology 2004;171(3):1330-5.
2003: Michael A O'Donnell
Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer.
Expert review of anticancer therapy 2003;3(6):809-21.
2003: Fadi N Joudi; Brian J Smith; Michael A O'Donnell; Badrinath R Konety
Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.
Urology 2003;62(6):1083-8.
2003: Badrinath R Konety; Sue A Joslyn; Michael A O'Donnell
Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base.
The Journal of urology 2003;169(3):946-50.
2003: Yi Luo; Xiaohong Chen; Michael A O'Donnell
Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect.
Cytokine 2003;21(1):17-26.
2001: Michael A O'Donnell; J Krohn; W C DeWolf
Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
The Journal of urology 2001;166(4):1300-4, discussion 1304-5.
2001: Yi Luo; Xiaohong Chen; R Han; Michael A O'Donnell
Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.
Clinical and experimental immunology 2001;123(2):264-70.
2000: Yi Luo; Xiaohong Chen; A Szilvasi; Michael A O'Donnell
Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity.
Molecular immunology 2000;37(9):527-36.
2000: Jodi K Maranchie; BT Bouyounes; Ping L Zhang; Michael A O'Donnell; I C Summerhayes; W C DeWolf
Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant.
The Journal of urology 2000;163(3):748-51.
2000: S K Clinton; E Canto; Michael A O'Donnell
Interleukin-12. Opportunities for the treatment of bladder cancer.
The Urologic clinics of North America 2000;27(1):147-55.
1999: Michael A O'Donnell; Yi Luo; Xiaohong Chen; A Szilvasi; Sharon E Hunter; S K Clinton
Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(8):4246-52.
1999: Yi Luo; Xiaohong Chen; R Han; M Chorev; William C DeWolf; Michael A O'Donnell
Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.
The Journal of urology 1999;162(4):1519-26.
1999: Yi Luo; Xiaohong Chen; TM Downs; W C DeWolf; Michael A O'Donnell
IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(4):2399-405.
1997: TM Downs; A Szilvasi; Michael A O'Donnell
Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B.
The Journal of urology 1997;158(6):2311-5.
1997: T Fujimoto; R B Duda; A Szilvasi; Xiaohong Chen; M Mai; Michael A O'Donnell
Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(12):5619-26.
1996: Yi Luo; A Szilvasi; Xiaohong Chen; W C DeWolf; Michael A O'Donnell
A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.
Clinical and diagnostic laboratory immunology 1996;3(6):761-8.
1996: T Fujimoto; Michael A O'Donnell; A Szilvasi; H Yang; R B Duda
Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro.
Cancer immunology, immunotherapy : CII 1996;42(5):280-4.
1995: Michael A O'Donnell; W C DeWolf
Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse.
Surgical oncology clinics of North America 1995;4(2):189-202.
1994: Michael A O'Donnell; A Aldovini; R B Duda; H Yang; A Szilvasi; R A Young; W C DeWolf
Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes.
Infection and immunity 1994;62(6):2508-14.